These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27693047)

  • 21. Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma.
    Lin CA; Rhodes CT; Lin C; Phillips JJ; Berger MS
    Cell Cycle; 2017 Apr; 16(8):765-775. PubMed ID: 28278055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
    Borodovsky A; Salmasi V; Turcan S; Fabius AW; Baia GS; Eberhart CG; Weingart JD; Gallia GL; Baylin SB; Chan TA; Riggins GJ
    Oncotarget; 2013 Oct; 4(10):1737-47. PubMed ID: 24077805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A vaccine targeting mutant IDH1 induces antitumour immunity.
    Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M
    Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
    Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
    Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
    Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
    Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
    Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
    Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
    Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
    Zhang N; Zheng B; Yao X; Huang X; Du J; Shen Y; Huang Z; Chen J; Lin Q; Lan W; Lin W; Ma W
    Biochem Biophys Res Commun; 2021 Apr; 551():38-45. PubMed ID: 33714758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-invasive in vivo assessment of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Yoshihara HA; Danforth OM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Nat Commun; 2013; 4():2429. PubMed ID: 24019001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prognostic Value of MRI Subventricular Zone Involvement and Tumor Genetics in Lower Grade Gliomas.
    Chiang GC; Pisapia DJ; Liechty B; Magge R; Ramakrishna R; Knisely J; Schwartz TH; Fine HA; Kovanlikaya I
    J Neuroimaging; 2020 Nov; 30(6):901-909. PubMed ID: 32721076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.
    Wang XW; Labussière M; Valable S; Pérès EA; Guillamo JS; Bernaudin M; Sanson M
    Biomed Res Int; 2014; 2014():198697. PubMed ID: 24895549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers.
    Karschnia P; Weller J; Blobner J; Stoecklein VM; Dorostkar MM; Rejeski K; Forbrig R; Niyazi M; von Baumgarten L; Dietrich J; Tonn JC; Thon N
    Sci Rep; 2021 Oct; 11(1):20045. PubMed ID: 34625590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.
    Müller T; Gessi M; Waha A; Isselstein LJ; Luxen D; Freihoff D; Freihoff J; Becker A; Simon M; Hammes J; Denkhaus D; zur Mühlen A; Pietsch T; Waha A
    Am J Pathol; 2012 Aug; 181(2):675-83. PubMed ID: 22688054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
    Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
    J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
    Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
    PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Pathogenesis of Low-Grade Glioma.
    Bready D; Placantonakis DG
    Neurosurg Clin N Am; 2019 Jan; 30(1):17-25. PubMed ID: 30470401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.